FindTrial
Sign In

The effect of viable Bifidobacterium quadruple on intestinal flora and expression of serum miR-103 in patients with type 2 diabetes

The effect of viable Bifidobacterium quadruple on intestinal flora and expression of serum miR-103 in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008039
Enrollment
Unknown
Registered
2016-03-02
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

test group : viable Bifidobacterium quadruple
control grpop: viable Bifidobacterium quadruple analog

Sponsors

the Central Hospital of Qingdao
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. type 2 diabetes; 2. HbA1c >=7% and <=10%; 3. Aged between 40-70 years, male or female; 4. voluntarily written informed consent.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes, gestational diabetes;Other special types of diabetes and unstable glycemic control,fasting blood glucose> 11.1 mmol/L; 2. Diabetic ketoacidosis or hyperosmolar nonketotic diabetic coma history; 3. Severe high blood pressure, heart disease, recent use of antibiotics, cancer and autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
intestinal flora;glycated hemoglobin;microRNA-103;—

Countries

China

Contacts

Public ContactYAO Min-xiu
yaominxiu@medmail.com.cn+86 18660229280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026